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Abstract 
BACKGROUND: Fibrosis in patients with Crohn’s disease (CD) results from an 
imbalance towards excessive fibrous tissue formation driven by fibroblasts. Activation 
of fibroblasts is linked to the B-cell lymphoma (BCL)2 family, which is involved in the 
induction of apoptosis. We investigated the impact of BCL2 repression on fibrogenesis.  
METHODS: The model of dextran sodium sulfate (DSS)-induced chronic colitis, and 
the heterotopic transplantation model of fibrosis were used. Following the 
administration of the BCL2 antagonist (ABT-737, 50 mg/kg/day), collagen layer 
thickness and hydroxyproline (HYP) content were determined. Fibroblasts were 
stimulated with the BCL2 antagonist (0.01 – 100 nM). BCL2, alpha smooth muscle 
actin (αSMA) and collagen I (COL1A1) were determined by qPCR, IF and WB. mRNA 
expression pattern was determined by Next Generation Sequencing (NGS).  
RESULTS: Collagen layer thickness was significantly decreased in both DSS-induced 
chronic colitis and the transplantation model of fibrosis upon BCL2 antagonist 
administration compared to vehicle. Decreased HYP content confirmed the preventive 
effects of the BCL2 antagonist on fibrosis. In vitro, a significant increase in PI+ / annexin 
V+ human colonic fibroblasts was determined by FACS upon treatment with high-dose 
BCL2 antagonist, at lower dose, αSMA, COL1A1 and TGF were decreased. NGS, IF 
and qPCR revealed decreased expression and nuclear translocation of GATA6 and 
SOX9, known for reprogramming fibroblasts.  
CONCLUSION: BCL2 antagonist administration partially prevented fibrogenesis in 
both fibrosis models. The BCL2 antagonist reduced the expression of TGFβ-induced 
factors involved in differentiation of myofibroblasts and therefore might represent a 
potential treatment option against CD-associated fibrosis.  
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Introduction  
The BCL2 family of apoptosis proteins decides over a cell´s life or death. Pro-survival 
BCL2 family members (BCL2, BCLXL, BCL, BCLB, myeloid cell leukemia sequence 
(MCL)1 and BCL2 related protein A1) interact with pro-apoptotic BCL2 family members 
(e.g. BCL2 associated X (BAX), BCL2 antagonist/killer 1 (BAK), BCL2 related ovarian 
killer protein (BOK) from the BAX group and BCL2-like protein 11 (BIM) from the BCL2 
homology (BH)3-only group), and induce or abolish apoptosis. The balance of those 
interactions determines the life cycle length of cells expressing the respective proteins.  
All pro-survival family members as well as pro-apoptotic BAX, BAK and BOK share 
four BH domains (1) and adopt similar structures (2). A hydrophobic surface groove is 
formed, a crucial interface for interactions for all pro-apoptotic BCL2 family members 
which share the BH3 domain necessary for dimerization and their killing activity. So-
called BH3-only proteins (such as BIM) are essential for the initiation of cell death. 
BH3-only proteins are induced transcriptionally or post-translationally by cytotoxic 
stress signals. Upon these apoptotic stimuli they translocate and the BH3 amphipathic 
helix of BH3-only proteins binds to the hydrophobic surface groove of BCL2-like 
molecules, and thereby antagonise their pro-survival function (3). These interactions 
primarily occur on intracellular membranes, particularly the mitochondrial outer 
membrane (4). BAX/BAK-like proteins are further downstream in apoptosis signaling 
and mediate mitochondrial membrane permeabilization by forming pores in the 
mitochondrial membrane, which eventually leads to apoptosis (5). Pro-survival BCL2 
stabilizes the mitochondrial membrane by inhibiting pore forming proteins BAX and 
BAK. Pro-apoptotic proteins like BIM can both antagonize the pro-survival function of 
BCL2 and directly bind to BAX and BAK in order to initiate apoptosis (6). 
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Activation and differentiation of a number of cell types, such as fibroblasts, is 
associated with increased cell survival, and therefore with the expression of members 
of the BCL2 family of proteins (7). As fibroblasts are activated during the process of 
fibrosis, altering BCL2 activity might be a potential treatment option. A number of BH3 
mimetic small molecules like Navitoclax, Venetoclax and ABT-737 (AbbVie, USA) have 
been developed as potent inhibitors of pro-survival BCL2, BCLXL and BCL (8, 9) and 
have been shown to disrupt the interactions of BCL2 family proteins, thereby inducing 
apoptosis in cancer. BCL2-specific Venetoclax was approved by the US FDA for 
chronic lymphocytic leukemia. ABT-737 has a high affinity to the hydrophobic surface 
groove of BCL2, BCLXL and BCLW but not markedly to MCL1 and A1 (4). ABT-737 
inhibits BCL2 by directly blocking pro-apoptotic BIM-binding sites and displacing BIM, 
which becomes freely available to interact with other BCL2 molecules in the cell. Thus, 
BIM can bind to pro-apoptotic BAX and BAK and trigger apoptosis by initiating the 
formation of pores on the mitochondrial surface.  
Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the 
intestinal wall and comprises two main conditions, namely ulcerative colitis (UC) and 
Crohn’s disease (CD). Severe and persistent mucosal tissue damage triggers an 
important inflammatory response, which in turn leads to the initiation of a reparatory 
process (10-12). Rapid and adequate healing is essential to restore a tight barrier and 
reduce the exposure of the underlying tissue to luminal antigens. Excessive 
extracellular matrix (ECM) deposition promotes fibrosis and impairs gastrointestinal 
function, constituting a common clinical problem in patients with CD. Fibrosis is 
increasingly recognised as an important cause of morbidity and mortality in IBD. 
Intestinal fibrosis leads to stricture formation in 30–50% of patients with CD (13, 14), 
and requires surgery in approximately 80% of these patients (13).  
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Myofibroblasts are one of the main producers of ECM components that are deposited 
during fibrosis. As adequate wound healing is the result of an exquisite balance 
between multiple pro- and anti-fibrotic stimuli on ECM-producing fibroblasts (15-18), a 
decrease in fibroblast death and fibroblast differentiation into myofibroblasts have been 
suggested to drive fibrosis. Myofibroblasts have migratory potential, (19-21) but can 
also be newly generated from several sources (22), including differentiation from stem 
cells, transdifferentiation from fibroblasts, smooth muscle cells and stellate 
myofibroblasts (23).  
M Hausmann                                       Therapeutic modulation of myofibroblast differentiation 
7 
 
Materials and Methods 
Patients 
Primary human fibroblast cultures were obtained from surgical specimens taken from 
healthy areas of the mucosa of a patient undergoing surgery for colorectal carcinoma 
or from the mucosa of patients with CD. The degree of inflammation was graded 
microscopically (“blind” pathologist) by determination of the inflammatory infiltrate of 
neutrophils, eosinophils, and lymphocytes: no inflammation, low degree of 
inflammation, and severe inflammation. Gender, age, clinical features and treatment 
of the patients are given in table 1. The study was approved by the Ethics Committee 
of the University of Regensburg and the University of Zurich and performed according 
to the Declaration of Helsinki. 
 
Isolation and culture of human and murine intestinal fibroblasts 
Human and murine intestinal fibroblasts were isolated and cultured as described 
previously (19). The mucosa from surgical specimens was cut into 1 mm pieces while 
the biopsies were used directly for the isolation of fibroblasts. Epithelial cells were 
removed in Hank’s Balanced Salt Solution without Ca2+ and Mg2+ (PAA, Colbe, 
Germany) with 2 mM EDTA (Sigma, Deisenhofen, Germany). The remaining tissue 
was digested for 30 minutes at 37°C with 1 mg/mL collagenase 1 (Sigma), 0.3 mg/mL 
DNase I (Boehringer, Mannheim, Germany), and 2 mg/mL hyaluronidase (Sigma) in 
PBS (Gibco, Karlsruhe, Germany). The isolated cells were cultured in 25 cm2 culture 
flasks (Costar, Bodenheim, Germany) with DMEM containing 10% fetal calf serum, 
penicillin (100 IE/mL), streptomycin (100 µg/mL), ciprofloxacin (8 µg/mL), gentamycin 
(50 µg/mL), and amphotericin B (1 µg/mL). Nonadherent cells were removed.  
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Animals 
Female B6-Tg(UBC-GFP)30Scha/J donor mice (GFP-Tg) weighing 20 g were bred 
locally in the animal facility of the University Hospital Zurich. C57BL/6J-Crl1 mice 
(C57BL/6) were obtained from Charles River. The animals received standard 
laboratory mouse food and water ad libitum. They were housed under specific 
pathogen-free conditions (SPF) in individually ventilated cages (IVC).  
 
Induction and treatment of chronic dextran sulfate sodium (DSS) colitis 
Female C57BL/6 weighing 20-25 g were used for the experiments and housed in IVC 
and under SPF for at least three weeks prior to testing. Chronic colitis was induced as 
described previously (24). During a cycle of chronic colitis mice received either 2.5 % 
DSS in drinking water or drinking water alone over seven days. In between, the animals 
were given 14-day periods of recovery. Mice received 3 cycles of DSS treatment as 
described above and were killed 2 weeks after completion of the last DSS cycle. 
 
ABT-737 preparation and application 
For in vitro experiments, ABT-737 was dissolved in DMSO to a stock concentration of 
5 mM. For in vivo experiments, ABT-737 was dissolved in polyethylene glycol, Tween 
80, dextrose solution and DMSO. ABT-737 was injected i.p. at a dose of 50 mg/kg/day 
during three cycles of DSS-induced chronic colitis. ABT-737 was injected i.p. at a dose 
of 50 mg/kg/day each day during two weeks in the experiment using the heterotopic 
intestinal transplant model. 
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Assessment of colonoscopy and histological score in mice  
Animals were anesthetized i.p. with a mixture of 90-120 mg ketamine (Narketan 10%, 
Vétoquinol AG, Bern Switzerland) and 8 mg xylazine (Rompun 2%, Bayer, 
Switzerland) per kg body weight, and examined with the Tele Pack Pal 20043020 (Karl 
Storz Endoskope, Germany). Mice were scored with a murine endoscopic index of 
colitis severity (MEICS) as described previously (25). For the assessment of the 
histological scores, 1 cm of the distal third of the colon was removed and scored as 
described (24, 26).  
 
Heterotopic intestinal transplant model 
The heterotopic mouse intestinal transplant model is an adaption of the heterotopic 
transplantation model of intestinal fibrosis in rats, which has been previously described 
in detail (27). Briefly, donor small bowel resections were extracted and transplanted 
subcutaneously into the neck of recipient animals. Donor small bowel proximal to the 
caecum was excised and flushed with 5 ml of 0.9% NaCl to remove stool, and divided 
into 10 mm parts. A small bowel resection was implanted into a subcutaneous pouch, 
and a single dose of Cefazolin (Kefzol®, 1 g diluted in 2.5 ml aqua dest) was applied 
i.p. as infection prophylaxis. Intestinal grafts were explanted seven days after 
transplantation.  
 
Collagen layer thickness measurement 
5 μm sections were examined with the Imager Z2 (Zeiss) and the software AxioVision 
(Zeiss). Collagen layer thickness was determined by a blinded investigator from at least 
eight places in representative areas at 10-fold magnification. 
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HYP assay 
HYP content was quantitated from freshly isolated small bowel and grafts using the 
HYP assay kit according to the manufacturer’s protocol (MAK008-1KT, Sigma-Aldrich). 
In brief, tissues (10–30 mg) were homogenized using gentleMACS Octo Dissociator 
(130-096-427, Miltenyl Biotec) and hydrolyzed in 12 M HCl (10 µL/mg tissue). 
Hydrolysates were transferred in duplicate to a 96 well plate and dried at 90°C. Dried 
samples were incubated each with 50 µL of chloramine T/oxidation buffer mixture (3 
µL of the chloramine T concentrate and 47 µL of the oxidation buffer) at room 
temperature for 5 minutes. 50 µL of the diluted DMAB reagent (25 µL 
dimethylaminobenzaldehyde, 25 µL perchloric acid/isopropanol) was subsequently 
added to each sample and the incubation was carried out at 60°C for 90 minutes for 
chromophore formation. Absorbance was read at 560 nm.  
 
TaqMan® gene expression assays 
For human: αSMA Hs00426835_g1, BCL2 Hs00608023_m1, BCLXL 
Hs00236329_m1, COL1A1 Hs00164004_m1, COL3A1 Hs00943809_m1, IL1β 
Hs01555410_m1, IL6 Hs00174131_m1, MMP3 Hs00968305_m1, MMP9 
Hs00234579_m1, TGFβ1 Hs00998133_m1, ELN Hs00355783_m1, LOXL2 
Hs00158757_m1, SOX9 Hs01001343_g1, GATA6 Hs00232018_m1, TIMP1 
Hs00171558_m1 and GAPDH 4326317E. 
For mice: αSma Mm00725412_s1, Bak1 Mm00432045_m1, Bax Mm00432051_m1, 
Bcl2 Mm00477631_m1*, BclXL Mm00437783_m1, Bim Mm00437796_m1, Mcl1 
Mm00725832_s1*, Mmp2 Mm00439498_m1, Mmp3 Mm00440295_m1, Mmp9 
Mm00442991_m1, Mmp13 Mm00439491_m1, Tgfβ1 Mm01178820_m1, Timp1 
Mm00441818_m1, Loxl2 Mm00804740_m1, Col1a1 Mm00801666_g1, Col3a1 
Mm01254476_m1, Il6 Mm00446190_m1 Ifnβ Mm00439552_s1, Ifnγ 
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Mm00801778_m1, Il10 Mm00439615_g1, Tnf Mm00443259_g1 and Gapdh 
4352339E. Relative gene expression was calculated using the ΔΔCt-method. 
 
Cell viability assay 
5000 cells per well were grown in triplicate in 96-well plates. Cells were starved for 24h 
before stimulation. Colorimetric assay (CK04; Dojindo Molecular Technologies) was 
performed according to the manufacturer’s protocol.  
 
Cell death assays 
Caspase-3/7 activity was quantified using the fluorogenic Ac-DEVD-AMC substrate 
(Enzo Life Sciences, Farmingdale, NY). Briefly, cells were grown in black 96-well plates 
with clear bottoms with respective treatments. 2x lysis buffer (100 mM HEPES, pH 7.4, 
200 mM NaCl, 0.2% CHAPS, 2 mM DTT, 0.2 mM EDTA) was added to each well and 
incubated for 15 min at 4°C. Caspase assay buffer (50 mM HEPES, pH 7.4, 100 mM 
NaCl, 0.1% CHAPS, 1 mM DTT, 0.1 mM EDTA, 10% glycerol) containing Ac-DEVD-
AMC (final 50 μM) was added to each well and release of AMC was measured after 1 
hour incubation at 37°C using a fluorescence microplate reader (Synergy 2, BioTek, 
Winooski, VT; excitation 360 nm, emission 460 nm). 
Numbers of living and apoptotic fibroblasts were determined by flow cytometry of 
annexin V- and propidium iodide (PI)-stained fibroblasts. Fibroblasts were 
resuspended in annexin V binding buffer, as indicated by the manufacturer, and 
stained with allophycocyanin (APC)-conjugated annexin V (Enzo Life Science, Basel, 
Switzerland; diluted 1 : 40) and PI (Sigma-Aldrich, St Louis, MO, USA; final 
concentration 25 mg/ml). Annexin V-/PI- cells were considered alive; apoptotic cells 
displayed staining for annexin V and PI. Fluorescence was measured by flow cytometry 
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using a BD fluorescence activated cell sorter (FACS)Canto II flow cytometer equipped 
with two lasers (excitation wave lengths: 488 and 633 nm). 
For IHC staining of formalin-fixed paraffin-embedded tissue samples, antigen retrieval 
was carried out using Cell Conditioning 1 (950-124, Ventana) for 90 min. Pre-treated 
tissue samples were incubated with the cleaved caspase-3 antibody (1:300 dilution, 
#9661, Cell Signaling Technology) for 44 min. Reactions were carried out on 
Benchmark Discovery (Ventana). For IHC staining of human fibroblast cultures, the 
same procedure was carried out as described above without antigen retrieval. Cleaved 
caspase-3 antibody was diluted 1:200 before usage. 
 
Next generation sequencing (NGS)  
Primary human colonic fibroblasts were stimulated either with vehicle or 5 ng/ml 
recombinant TGFβ in the presence or absence of 10 nM ABT-737. Two independent 
experiments were performed and NGS was performed using total RNA that passed 
Tapestation (Agilent) quality control (RIN > 8.3). Illumina NGS was performed by the 
Functional Genomics Center Zurich. For further analyses STRING software according 
to the PathCards from the Weizmann Institute of Science was used. Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed genes from 
the TGFβ signaling pathway to be increased > 2-fold upon recombinant TGFβ and 
decreased > 2-fold upon additional ABT-737. KEGG signaling pathway analyses 
“regulation of stem cell differentiation”, “regulation of cell development” and “regulation 
of cell differentiation” were applied. 
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Western blot 
Western blots were performed using goat anti-mouse αSMA (PA5-18292, Thermo 
Fisher Scientific), rabbit anti-human Bcl2 (#2870, Cell Signaling Technology), rabbit 
anti-human BclXL (#2764, Cell signaling Technology), rabbit anti-mouse βactin 
(#4970, Cell Signaling Technology), horseradish peroxidase-conjugated secondary 
antibody goat anti-rabbit (#sc-2004, Santa Cruz) and horseradish peroxidase-
conjugated secondary antibody donkey anti-goat (#sc-2020, Santa Cruz). 
Luminescence was quantified using ImageJ. 
 
Statistical analysis 
Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance 
(ANOVA) on ranks, all pairwise multiple comparison procedures, Tukey’s test, Holm-
Sidak method or unpaired t-test, as indicated. Differences were considered significant 
at a p-value of < 0.05 and highly significant at a p-value of < 0.01 and p-value of < 
0.001.  
 
Ethical considerations 
Experiments with human primary fibroblasts were approved by the local ethical 
committees (EK-1316). 
The experimental protocol was approved by the local Animal Care Committee of the 
University of Zurich (registration number ZH183/2014). 
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Results 
The BCL2 antagonist reduced fibrosis in DSS-induced chronic colitis 
We investigated whether BCL2 antagonist administration reduces fibrosis in the model 
of DSS-induced chronic colitis (n = 39 mice). Successful induction of colitis was 
confirmed by an intermittent body weight loss, a significant increase in spleen weight, 
and shortening of the colon compared to water control (supplementary figure 1). Due 
to its known anti-inflammatory properties, BCL2 antagonist was efficacious in 
ameliorating colitis confirmed by a significantly decreased MEICS, a decreased 
histological score, and a reduction in the mRNA expression of Ifnγ and Tnf compared 
to vehicle-treated mice (supplementary figure 2).  
To determine fibrosis, we performed Sirius red staining to assess collagen deposition. 
Mice without DSS-induced colitis displayed a normal collagen layer thickness in the 
colon of both vehicle- and BCL2 antagonist-treated mice (figure 1A). During DSS 
administration, collagen deposition was significantly increased compared to water 
controls. Microscopy evidenced a significant decrease in collagen layer thickness in 
the colon from mice treated with the BCL2 antagonist in comparison to colon from 
vehicle-treated mice (figure 1A). HYP assay confirmed that the BCL2 antagonist 
significantly decreased collagen deposition in comparison to vehicle-treated mice 
(figure 1B). IHC staining of colon histological cross sections revealed an increase in 
cleaved caspase 3 positive foci in the lamina propria and Peyer’s patches upon 
treatment with the pro-apoptotic BCL2 antagonist compared to vehicle in DSS-induced 
colitis (figure 1C). Transcriptional expression of αSma and Tgf was decreased in colon 
from BCL2 antagonist-treated mice compared to vehicle-treated mice (figure 1D), in 
contrast, tissue inhibitor of metalloproteinase (Timp)1 was increased in colon from 
BCL2 antagonist-treated mice compared to vehicle-treated mice (figure 1D).  
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The BCL2 antagonist reduced fibrosis in the transplantation model of fibrosis 
We next investigated whether BCL2 antagonist administration would also reduce 
fibrosis in the heterotopic transplantation mouse model of intestinal fibrosis (n = 25 
mice). Stained histological cross sections from freshly isolated small intestine showed 
an open lumen and distinctive epithelial crypts. Seven days after transplantation, the 
lumen of intestinal grafts was obstructed by granulation and fibrotic tissue (figure 2A). 
Epithelial structure was almost lost in heterotopic intestinal isografts. Microscopy 
evidenced a decrease in collagen deposition in freshly isolated small bowel and in 
intestinal transplants upon treatment with the BCL2 antagonist compared to vehicle 
under polarizing light and transmission light. Collagen layer thickness was significantly 
decreased in harvested grafts from mice upon treatment with the BCL2 antagonist in 
comparison to grafts from vehicle-treated mice for both polarizing light (figure 2A) and 
transmission light (supplementary figure 3). HYP assay confirmed that BCL2 
antagonist treatment significantly decreased collagen content in comparison to vehicle-
treated mice (figure 2B).  
Heterotopic transplantation of small bowel resections in mice was followed by a 
significant increase in the mRNA expression of both Col1a1 and Col3a1 compared to 
freshly isolated small bowel (figure 2C). The grafts showed a trend towards a 
decreased Col1a1 and Col3a1 mRNA expression upon administration of the BCL2 
antagonist compared to vehicle. Next, we determined the expression of Mmp2 and 
Timp1 in intestinal transplants by qPCR. Transplantation was followed by a significant 
increase in Mmp2 (figure 2C). Grafts from mice treated with the BCL2 antagonist 
showed a trend towards a decreased Mmp2 expression compared to vehicle. In 
contrast, tissue inhibitor Timp1 was increased upon treatment with BCL2 antagonist.  
M Hausmann                                       Therapeutic modulation of myofibroblast differentiation 
16 
 
Treatment with BCL2 antagonist decreases the differentiation of murine 
myofibroblasts 
Next, we sought to determine the impact of BCL2 antagonist treatment on the 
differentiation of primary murine colonic fibroblasts. Cell viability remained unchanged 
in murine fibroblasts following TGFβ-stimulation and administration of the BCL2 
antagonist (figure 3A). TGFβ-induced transcriptional expression of αSma decreased in 
a dose-dependent manner in the presence of the BCL2 antagonist indicating that the 
BCL2 antagonist hinders fibroblast proliferation (figure 3B). Western blot analysis 
revealed significantly increased αSMA protein levels in the presence of TGFβ, but a 
dose-dependent decrease in αSMA upon BCL2 antagonist treatment (figure 3C). IF 
analysis confirmed a decrease in αSMA protein upon BCL2 antagonist treatment in the 
absence (figure 3D) or presence of TGFβ (figure 3E).  
TGFβ also significantly increased mRNA expression of the structural protein Col1a1 in 
primary murine fibroblasts compared to fibroblasts without TGFβ stimulation (figure 
4A). Conversely, Col1a1 and Col3a1 expression was decreased upon BCL2 
antagonist treatment in a dose-dependent manner (figure 4A). TGFβ significantly 
increased collagen crosslinking enzyme Loxl2, a crucial protein for the stabilization of 
collagen fibrils and fibers in the ECM (figure 4B). The BCL2 antagonist significantly 
decreased TGFβ-induced Loxl2 in a dose-dependent manner (figure 4B).  
Similarly, TGFβ-induced Timp1 expression decreased upon BCL2 antagonist 
treatment (figure 4C). Following TGFβ stimulation, mRNA of ECM-degrading enzymes 
Mmp3 and Mmp9 increased (supplementary figure 4A and B). Mmp3 decreased upon 
high-dose BCL2 antagonist treatment (supplementary figure 4A), but Mmp9 increased 
in the presence of the BCL2 antagonist (supplementary figure 4B). Mmp13 was not 
affected by TGFβ or BCL2 antagonist (supplementary figure 4C). 
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Next, we analyzed the mRNA expression of pro- and anti-inflammatory cytokines upon 
TGFβ-induced differentiation of murine fibroblasts in the presence of the BCL2 
antagonist. Stimulation with TGFβ significantly increased endogenous Tgfβ, which acts 
as an anti-inflammatory and pro-fibrotic cytokine (figure 4D). The BCL2 antagonist 
significantly decreased Tgfβ in a dose-dependent manner. Anti-inflammatory Il10 was 
not detectable in fibroblasts regardless of TGFβ and BCL2 antagonist stimulation (not 
shown). Pro-inflammatory Il6 was significantly increased following TGFβ treatment, 
and significantly decreased in the presence of the BCL2 antagonist (figure 4E). Pro-
inflammatory Ifnγ was not detectable in fibroblasts regardless of TGFβ and BCL2 
antagonist stimulation (not shown). 
Further, we analysed the mRNA expression of members of the BCL2 family of 
apoptosis proteins. Pro-survival BclXL, Bcl2 and Mcl1 were not regulated following 
TGFβ stimulation (supplementary figure 5A). BclXL increased following administration 
of BCL2 antagonist in a dose-dependent manner compared to vehicle. Pro-apoptotic 
Bim, Bak and Bax were not regulated in the presence or absence of TGFβ and the 
BCL2 antagonist stimulation (supplementary figure 5B). 
Additionally, in the murine 3T3 fibroblast cell line TGFβ-mediated Mmp3 and Il6 mRNA 
expression was reduced in the presence of the BCL2 antagonist confirming the results 
obtained with primary murine fibroblasts (supplementary figure 6). Il10 and Ifnγ were 
not detectable in 3T3 regardless of TGFβ and BCL2 antagonist stimulation (not 
shown). 
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Treatment with the BCL2 antagonist decreased differentiation of human 
myofibroblasts 
Next, we determined the impact of BCL2 antagonist treatment on differentiation of 
primary human colonic fibroblasts. Cell viability increased following TGFβ stimulation 
in human fibroblasts and showed a trend towards a decrease upon administration of 
BCL2 antagonist (figure 5A). Accordingly, caspase 3/7 activity showed a trend towards 
an increase upon BCL2 antagonist treatment (figure 5B). The presence of cleaved 
caspase 3 positive fibroblasts upon treatment with high-dose BCL2 antagonist was 
confirmed by IHC (figure 5C). A significant increase in PI+ / annexin V+ human colonic 
fibroblasts was determined by flow cytometry upon treatment with high-dose BCL2 
antagonist (figure 5D).  
To elucidate whether TGF-β-mediated differentiation of human fibroblasts is 
decreased upon BCL2 antagonist treatment, αSMA expression was analyzed. 
Transcriptional expression of αSMA was significantly increased upon TGFβ treatment 
but decreased in the presence of the BCL2 antagonist (figure 6A, supplementary figure 
7A, patient 2). Furthermore, IF analysis showed a decrease of αSMA protein upon 
antagonist treatment (figure 6B). Similarly, TGFβ-induced COL1A1, COL3A1 and 
TGFβ mRNA expression decreased upon antagonist treatment in human fibroblasts 
(figure 6C and D, supplementary figure 7B and C, patient 2). Elastin mRNA (ELN) 
decreased upon BCL2 antagonist treatment (supplementary figure 8A, patient 2), 
whereas LOXL2 remained unchanged regardless of TGFβ and BCL2 antagonist 
stimulation (supplementary figure 8B, patient 2). MMP3, MMP9 and TIMP1 did not 
change significantly upon BCL2 antagonist treatment (supplementary figure 9A and 
B). MMP13, IL6, IFNγ and IL10 were not detectable in human primary fibroblasts 
regardless of TGFβ and BCL2 stimulation (not shown). 
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We next determined the effects of the BCL2 antagonist on the expression of BCLXL 
and BCL2 in primary human colonic fibroblasts. BCLXL mRNA remained unchanged 
in the presence of both TGFβ and the BCL2 antagonist (supplementary figure 10A). In 
contrast, BCL2 protein decreased upon BCL2 antagonist treatment as shown by 
Western blot (figure 7A). BCL2 mRNA was decreased following TGFβ stimulation and 
increased upon antagonist treatment, but not significantly (supplementary figure 10B, 
C). In contrast, Western blot revealed a decrease in BCL2 protein upon BCL2 
antagonist treatment (figure 7B).  
 
Treatment with the BCL2 antagonist decreased nuclear translocation of GATA6 
and pSOX9  
We determined the effects of BCL2 antagonist treatment on the mRNA expression 
pattern in primary human colonic fibroblasts by NGS. A total of 20400 genes were 
identified. Following TGFβ stimulation, 844 genes were increased > 2-fold compared 
to vehicle in two independent experimental rounds. Upon additional stimulation with 
the BCL2 antagonist, 247 of these genes were decreased > 2-fold compared to TGFβ 
stimulation alone in both experimental rounds (figure 8A and supplementary table). 
Regulated genes include a number of cytoskeletal proteins and ECM components 
(ACTB, ACTC1, ACTG2, COL1A1, COL16A1, COL4A3, COMP, ELN, EMILIN2, 
FIBCD1). KEGG analyses revealed regulated genes from the TGFβ signaling pathway 
(TGFB2, THBS1, LEFTY2, NOG, CDKN2B), and the transcription factors GATA 
binding protein 6 (GATA6) and SRY-Box 9 (SOX9).  
GATA6 performs its biological activity after being phosphorylated and translocated to 
the nucleus, but an anti-pGATA6 ab is not commercially available. On the other hand, 
total GATA6 expression is induced by TGFβ during myofibroblast differentiation. 
Therefore, we performed qPCR and IF using anti-GATA6 ab. TGFβ stimulation 
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significantly increased GATA6 in human fibroblasts compared to vehicle (figure 8B) 
but expression decreased in the presence of the BCL2 antagonist. GATA6 protein was 
detected in human fibroblasts regardless of TGFβ stimulation (figure 8C) and was 
decreased upon BCL2 antagonist treatment.  
TGFβ-induced SOX9 mRNA expression was decreased upon BCL2 antagonist 
stimulation compared to vehicle in human fibroblasts (figure 8B). Anti-pSOX9 ab did 
not work on human fibroblasts, but showed cross-reactivity on primary murine 
fibroblasts. pSOX9 was detected in the nuclei of murine fibroblasts upon TGF-β 
treatment, but the antagonist decreased pSOX9 in a dose-dependent manner (figure 
8D). Similarly, the BCL2 antagonist decreased TGFβ-mediated SOX9 accumulation in 
the nuclei of human fibroblasts (figure 8E). 
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Discussion  
In the present study, we show that the BCL2 antagonist ABT-737 hindered the 
development of intestinal fibrosis in both the DSS mouse model of chronic colitis and 
the mouse heterotopic transplantation model of fibrosis, indicated by a significant 
decrease in collagen mRNA expression, collagen layer thickness and HYP content. 
Interestingly, pro-apoptotic ABT-737 also has anti-inflammatory properties. Recent 
studies showed that the BCL2 antagonist has a direct effect on activated lymphocytes. 
The BCL2 family plays a critical role in controlling immune responses by regulating the 
expansion and contraction of the activated lymphocyte population via apoptosis (28-
32). In IBD, the inflammatory state is sustained by an exaggerated response of T-
lymphocytes to luminal antigens associated with an increased resistance to apoptosis 
(31). ABT-737 is effective in limiting the persistence of lymphocytes in spontaneous 
mouse models of colitis (33). Regulation of inappropriate survival of lymphocytes by 
ABT-737 is also effective in treating animal models of autoimmune diseases (34), 
arthritis (35) and lupus (36). Consequently, regulation of inappropriate survival of 
lymphocytes by the BCL2 antagonist may also represent a therapeutic anti-
inflammatory strategy in IBD.  
In the model of DSS-induced chronic colitis, fibrosis is induced through a recurrent 
damage of the integrity of the mucosal barrier resulting in long-running lymphocyte 
infiltration and chronic colitis. At first hand, ABT-737 could decrease inflammation over 
time, thereby limiting the basis for the initiation of fibrosis. In experiments presented in 
this work, this is evidenced by increased apoptosis in Peyer’s patches and the lamina 
propria, and a decrease in the expression of pro-inflammatory cytokines. Targeting 
BCL2 family proteins to initiate lymphocyte apoptosis may contribute to decreased 
fibrogenesis, but BCL2 antagonists could also have a more wide effect on fibroblast 
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differentiation. The BCL2 antagonist is also effective to reduce fibrosis in the much 
faster heterotopic transplantation mouse model of intestinal fibrosis, characterized by 
increased TGFβ levels, hypoxia and neovascularization of the fibrotic graft. We could 
also demonstrate anti-fibrotic effects of the BCL2 antagonist on murine and human 
colonic fibroblasts. High concentrations of ABT-737 induce apoptosis in colonic 
fibroblasts in vitro as shown by caspase activity assay, cleaved caspase 3 IHC and 
flow cytometry. The BCL2 antagonist ABT-737 shows a potent action against various 
transformed cells while exhibiting minimal toxicity toward normal cells, e.g. intestinal 
epithelial cells (37). Results from our in vitro experiments showed that the BCL2 
antagonist does not alter intestinal fibroblast viability at low concentrations, but still 
reverses TGFβ mediated effects. Hallmarks of fibroblast differentiation and 
fibrogenesis, such as increased expression of αSMA and COL1A1 are inhibited upon 
BCL2 antagonist treatment.  
A reasonable number of genes for cytoskeletal proteins and ECM components were 
shown to be inhibited upon BCL2 antagonist treatment compared to vehicle. However, 
ECM-degrading MMPs and TIMP1 were shown to be regulated paradoxically. The 
interaction between MMPs and TIMP1 is highly controlled and characterized by an 
interplay of increased and declined expression (reviewed in (38) for liver fibrosis). 
Expression levels may vary depending on the time point for data collection, scheduled 
after several weeks for in vivo experiments compared to a 24h stimulation for cell lines.  
Differentiation of colonic fibroblasts is considered a main driving factor in intestinal 
fibrosis. Myofibroblasts, representing the activated phenotype, can differentiate from 
stem cells (22) or be newly generated by trans-differentiation from fibroblasts, smooth 
muscle cells and stellate myofibroblasts (23). We could show a decrease in the 
expression and nuclear translocation of the transcription factors GATA6 and SOX9 
upon BCL2 antagonist treatment in primary intestinal fibroblasts. GATA6 has been 
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previously shown to participate in the differentiation of fibroblasts into myofibroblasts 
in idiopathic pulmonary fibrosis (IPF) lungs (39). The inhibition of GATA-6 in lung 
fibroblasts showed that the transcription factor mediates aSMA–induction upon TGFβ 
stimulation. SOX9 has been identified as an important link between differentiation, 
proliferation and apoptosis in rat mesenchymal stem cells (40). SOX9 modulates 
BCL2-dependent apoptosis in undifferentiated adult mesenchymal stem cells, 
emphasizing the importance for successful repair and regeneration in tissues and 
organs in adults. Taken together these results point to that BCL2 antagonist treatment 
reduces progressive differentiation of human intestinal fibroblasts into myofibroblasts.  
Intestinal fibrosis is viewed as a unidirectional process consisting of a chronic response 
of the digestive tract, in which inflammation induces local fibroblasts to multiply, 
become activated and deposit extracellular matrix proteins as part of the wound healing 
process (41). There is evidence that intestinal fibrogenesis, once initiated, is self-
perpetuating (42) and constitutes a very early process associated with inflammation 
(43). Results from our own studies support this hypothesis as we determined a rapid 
increase of collagen layer thickness and rapid increase of TGFβ in grafts shortly after 
transplantation (44). Administration of anti-inflammatory agents effectively treats 
inflammatory flares, but may not be able to alter the course of intestinal fibrosis and 
prevent the formation of strictures (45, 46). Despite earlier initiation of 
immunosuppressants or biologicals during the course of CD, the percentage of 
patients requiring intestinal surgery due to the occurrence of stricturing complications 
has only decreased slightly (47). But potent anti-inflammatory agents alone may not 
prevent fibroblast recruitment and differentiation.  
Activation and differentiation of fibroblasts is linked to the expression of members of 
the BCL2 family of proteins, and there is a particular interest in the development of 
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inhibitors of the BCL2 family for the treatment of fibrotic diseases. We could show a 
decrease in BCL2 and BCLXL upon BCL2 antagonist compared to vehicle. However, 
qPCR showed a trend to increased murine BclXL, human BCL2 and BCLXL what could 
be a compensation of decreased protein level. There is strong evidence that 
antagonizing pro-survival BCL2 family members induces apoptosis in activated 
fibroblasts but not in quiescent fibroblasts. Thus, selective inhibition of BCLXL by A-
1331852 or BCLXL-specific siRNA silencing induced apoptosis in activated fibroblasts 
but had no effect on quiescent fibroblasts (48). Treatment with A-1331852 resulted in 
a significant reduction of liver fibrosis in a murine model of biliary fibrosis, possibly as 
a result of a dual effect on activated fibroblasts and senescent cholangiocytes. Cardiac 
fibrosis has been partially prevented through microRNA-21-mediated decrease of 
BCL2 in cultured cardiac fibroblasts and in a rat model of cardiac fibrosis (49). Dermal 
myofibroblasts isolated from patients with systemic sclerosis show increased BCL2 
compared to fibroblasts from control subjects Decreasing BCL2 using microRNA-29a 
increased apoptosis in dermal fibroblasts (50). 
Further, there is extensive literature on myofibroblast apoptosis resistance being 
associated with the progression of IPF (51). Pathologic lesions called “fibroblastic foci” 
have been associated with IPF (52) and are characterized by prominent epithelial cell 
apoptosis but insufficient mesenchymal cell apoptosis (53, 54). While there is no robust 
fibroblast proliferation within fibroblast foci (39, 55), decreased fibroblast apoptosis has 
been suggested as a mechanism underlying the accumulation of these cells (55, 56). 
Fibroblastic foci were positive for the transcription factor GATA6, but negative for Ki67 
and caspase 3 confirming the absence of apoptosis (39). TGFβ and endothelin-1 
promote myofibroblast apoptosis resistance via activation of focal adhesion kinase and 
PI3K/AKT signaling pathways (57, 58), which in turn induce the expression of anti-
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apoptotic X-linked inhibitor of apoptosis and survivin, which are increased in fibroblast 
foci of IPF tissue (59, 60). Additionally, myofibroblasts isolated from lungs of patients 
suffering from IPF show increased BCL2 compared to fibroblasts from control subjects 
(61). Decreasing Bcl2 during the post-inflammatory fibrotic phase of lung injury 
protects mice from experimental lung fibrosis (61).  
In summary, we showed that low concentrations of the antagonist of pro-apoptotic 
BCL2 prevents fibroblast activation and differentiation of fibroblasts into 
myofibroblasts. High concentrations induce apoptosis in fibroblasts. ABT-737 partially 
prevents intestinal fibrogenesis in the DSS-induced model of colitis and in a heterotopic 
transplantation model of fibrosis. BCL2 antagonists may therefore represent a new 
treatment option to prevent fibrogenesis in IBD patients, and to reduce colitis through 
the reduction of lymphocytes.   
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Figure legends 
 
Figure 1: The BCL2 antagonist reduces fibrosis in DSS-induced chronic colitis. 
Mice received 3 cycles of DSS treatment and were killed 2 weeks after completion of 
the last cycle. BCL2 antagonist was injected during three cycles of DSS-induced 
chronic colitis. (A) Sirius red staining. Transmission light microscopy confirmed 
significantly decreased collagen layer thickness upon BCL2 antagonist treatment 
compared to vehicle. Thickness was calculated from at least eight places in 
representative areas at 10-fold magnification for each single tissue sample. Mean 
value and standard deviation are shown. (B) HYP assay. (C) Cleaved caspase 3 IHC. 
(D) qPCR for αSma, Tgf and Timp1 (* p < 0.05, ** p < 0.01, ANOVA, t-test). 
 
Figure 2: BCL2 antagonist administration significantly reduces collagen layer 
thickness in grafts from the heterotopic transplantation model. BCL2 antagonist 
was injected each day during two weeks in the experiment. (A) Sirius Red staining. 
Polarizing light microscopy confirmed significantly decreased collagen layer thickness 
upon treatment with the BCL2 antagonist compared to vehicle. Thickness was 
calculated from at least eight places in representative areas at 10-fold magnification 
for each single graft. Mean value and standard deviation are shown. (B) HYP assay. 
(C) qPCR for Col1a1, Col3a1, Mmp2 and Timp1 (* p < 0.05, ** p < 0.01, *** < 0.001, 
ANOVA, Dunn’s multiple comparison test).   
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Figure 3: The BCL2 antagonist decreases αSMA in murine fibroblasts. Fibroblasts 
were stimulated with 5 ng/ml TGFβ, BCL2 antagonist stimulation for 24 h with the 
concentrations indicated. (A) Viability assay. (B) qPCR for αSma. (C) Western blot for 
αSMA, representative image for n = 3, densitometry. (D) IF, gain 900 V used for signal 
amplification. (E) IF of TGF-β stimulated fibroblasts, gain 600 V, 63-fold magnification, 
blue = DAPI, green = αSMA (* p < 0.05, ANOVA, Dunn’s multiple comparison test). 
 
Figure 4: The BCL2 antagonist decreased murine fibroblast differentiation. 
Fibroblasts were stimulated with 5 ng/ml TGFβ, BCL2 antagonist stimulation for 24 h 
with the concentrations indicated. qPCR for (A) Col1a1 and Col3a1, (B) Loxl2, (C) 
Timp1, (D) Tgfβ and (E) Il6 (* p < 0.05, ANOVA, Dunn’s multiple comparison test). 
 
Figure 5: High concentrations of the BCL2 antagonist increased apoptosis in 
human fibroblasts. Fibroblasts were stimulated with 5 ng/ml TGFβ, BCL2 antagonist 
stimulation for 24 h with the concentrations indicated. (A) Viability assay. (B) Caspase 
3/7 activity. (C) IHC for cleaved caspase 3. (D) Flow cytometry (*** p < 0.001, ANOVA, 
Dunn’s multiple comparison test). 
 
Figure 6: The BCL2 antagonist decreased αSMA in human fibroblasts. Fibroblasts 
were stimulated with 5 ng/ml TGFβ, BCL2 antagonist stimulation for 24 h with the 
concentrations indicated. (A) qPCR for αSMA. (B) IF for αSMA, 63-fold magnification, 
blue = DAPI, green = αSMA. (C) qPCR for COL1A1 and COL3A1. (D) qPCR for TGF 
(* p < 0.05, ANOVA, Dunn’s multiple comparison test for 6A and t-test for 6C and D). 
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Figure 7: The BCL2 antagonist decreased BCLXL and BCL2 in human fibroblasts. 
Fibroblasts were stimulated with 5 ng/ml TGFβ, BCL2 antagonist stimulation for 24 h 
with the concentrations indicated. (A) Western blot for BCLXL. (B) Western blot for 
BCL2 (* p < 0.05, ** p < 0.01, ANOVA, Dunn’s multiple comparison test). 
 
Figure 8: The BCL2 antagonist decreased nuclear translocation of GATA6 and 
pSOX9 in fibroblasts. Fibroblasts were stimulated with 5 ng/ml TGFβ, BCL2 
antagonist stimulation for 24 h with the concentrations indicated. (A) NGS cluster plot. 
(B) qPCR for GATA6 and SOX9. (C) IF in human fibroblasts from patient 1, blue = 
DAPI, red = GATA6. (D) IF in murine fibroblasts, blue = DAPI, red = pSOX9. (E) IF in 
human fibroblasts from patient 1, blue = DAPI, red = SOX9 (63-fold magnification, * p 
< 0.05, ANOVA, Dunn’s multiple comparison test). 
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 Gender Age at time of 
fibroblast isolation 
(years) 
 
Disease,  
intestinal segment 
Disease behavior Treatment Date of fibroblast 
isolation 
Date cryo-
preservation 
Date of renewed 
culture 
Passage 
number 
1 female 52 CD, colon Mild inflammation,  
no fibrostenotic segment,  
no fistla 
 
Azathioprine 20 Sept 2001 19 Oct 2001 Feb 2016 12-20 
2 female 70 Rectum-carcinoma No inflammation,  
no fibrostenotic segment 
 
information not 
interrogated 
02 Dec 1999 10 Feb 2000 Feb 2016 12-20 
Table 1: Characteristics of patients for isolation and culture of human intestinal fibroblasts 
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Supplementary table: Illumina NGS using total RNA (RIN > 8.3) from primary human colonic fibroblasts from patient 1. NGS was 
performed by the Functional Genomics Center Zurich. Regulation was confirmed in two independent experimental rounds. Genes 
listed here were increased at least > 2-fold upon recombinant TGF-β and decreased at least > 2-fold upon additional ABT-737. Random colour 
code. 
n-fold increase upon 
rTGF-β 
m-fold decrease upon 
additional ABT-737 
gene_name 
 
description 
 
396.6978 0.3504 TGFB2 transforming growth factor beta 2 
167.1609 0.4818 TGFBI transforming growth factor beta induced 
110.0582 0.4060 ACTB actin beta 
77.8927 0.4202 ACTG1 actin gamma 1 
76.1643 0.2249 COL4A3 collagen type IV alpha 3 chain 
73.4180 0.3621 COL16A1 collagen type XVI alpha 1 chain 
56.6342 0.3751 COL1A1 collagen type I alpha 1 chain 
38.5680 0.3231 TGFB1I1 transforming growth factor beta 1 induced transcript 1 
37.3079 0.3603 EMILIN2 elastin microfibril interfacer 2 
36.5515 0.2195 TNFRSF11B TNF receptor superfamily member 11b 
34.6266 0.1445 ACTA2 actin, alpha 2, smooth muscle, aorta 
32.6911 0.0624 ACTC1 actin, alpha, cardiac muscle 1 
31.8816 0.0925 ACTG2 actin, gamma 2, smooth muscle, enteric 
31.7181 0.1635 C1QTNF3 C1q and tumor necrosis factor related protein 3 
31.0263 0.4431 FIBCD1 fibrinogen C domain containing 1 
30.9796 0.0248 LEFTY2 left-right determination factor 2 
30.9685 0.0628 MAMDC2 MAM domain containing 2 
30.2886 0.1794 EDN1 endothelin 1 
25.4419 0.2735 COMP cartilage oligomeric matrix protein 
23.9765 0.0574 ELN elastin 
22.6845 0.0010 NPPB natriuretic peptide B 
21.8715 0.0051 CYP24A1 cytochrome P450 family 24 subfamily A member 1 
21.2773 0.0169 IGF1 insulin like growth factor 1 
21.0261 0.0221 PLN phospholamban 
20.8501 0.0229 NOTUM NOTUM, palmitoleoyl-protein carboxylesterase 
20.5072 0.0262 KRT80 keratin 80 
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20.2989 0.0267 ASB2 ankyrin repeat and SOCS box containing 2 
20.2166 0.0297 EXTL1 exostosin like glycosyltransferase 1 
20.1477 0.0333 METTL21C methyltransferase like 21C 
20.0597 0.0338 AMDHD1 amidohydrolase domain containing 1 
19.3253 0.0385 ABC7-42404400C24.1 
19.3124 0.0429 NXPH3 neurexophilin 3 
19.2814 0.0439 HBD hemoglobin subunit delta 
19.2655 0.0443 KRT86 keratin 86 
18.3833 0.0473 TAS2R31 taste 2 receptor member 31 
18.2893 0.0525 ASB9 ankyrin repeat and SOCS box containing 9 
18.1638 0.0545 RP11-136C24.3  
17.3237 0.0590 GBP1 guanylate binding protein 1 
17.0576 0.0638 CXCL10 C-X-C motif chemokine ligand 10 
17.0468 0.0645 CAPN6 calpain 6 
16.8788 0.0654 MECOM MDS1 and EVI1 complex locus 
16.7453 0.0864 SFRP4 secreted frizzled related protein 4 
16.0284 0.0898 SYT12 synaptotagmin 12 
15.4935 0.0915 KRBOX1 KRAB box domain containing 1 
15.2777 0.0958 KCNMB1 potassium calcium-activated channel subfamily M regulatory beta subunit 1 
14.7023 0.0975 PPP1R14A protein phosphatase 1 regulatory inhibitor subunit 14A 
14.6936 0.1027 MUM1L1 MUM1 like 1 
14.4584 0.1103 GATM glycine amidinotransferase 
13.9967 0.1113 FAM150A family with sequence similarity 150 member A 
13.6053 0.1132 PCSK1N proprotein convertase subtilisin/kexin type 1 inhibitor 
13.1272 0.1162 SERTAD4 SERTA domain containing 4 
13.0214 0.1182 MYLK2 myosin light chain kinase 2 
12.8480 0.1182 CNN1 calponin 1 
12.7848 0.1184 LDB3 LIM domain binding 3 
12.6418 0.1184 RASL12 RAS like family 12 
12.3655 0.1200 MEGF6 multiple EGF like domains 6 
12.2294 0.1203 HSD17B6 hydroxysteroid 17-beta dehydrogenase 6 
11.9969 0.1240 DPT dermatopontin 
11.7727 0.1285 LRRN3 leucine rich repeat neuronal 3 
11.6885 0.1347 SCN7A sodium voltage-gated channel alpha subunit 7 
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11.6652 0.1375 HSPB1 heat shock protein family B (small) member 1 
11.4853 0.1389 PLEKHA7 pleckstrin homology domain containing A7 
11.3302 0.1428 MYH11 myosin heavy chain 11 
11.2719 0.1466 CRISPLD2 cysteine rich secretory protein LCCL domain containing 2 
11.1907 0.1467 CSDC2 cold shock domain containing C2 
11.1419 0.1512 DKK2 dickkopf WNT signaling pathway inhibitor 2 
10.8727 0.1529 LHFPL1 lipoma HMGIC fusion partner-like 1 
10.7677 0.1575 LBP lipopolysaccharide binding protein 
10.5703 0.1589 DUSP26 dual specificity phosphatase 26 (putative) 
10.5631 0.1599 KRT18 keratin 18 
10.5593 0.1605 KRT7 keratin 7 
10.5207 0.1666 KANK4 KN motif and ankyrin repeat domains 4 
10.4254 0.1691 WISP1 WNT1 inducible signaling pathway protein 1 
10.4119 0.1693 LIMS2 LIM zinc finger domain containing 2 
10.3276 0.1695 RASGRP3 RAS guanyl releasing protein 3 
10.2991 0.1703 INMT indolethylamine N-methyltransferase 
10.2087 0.1704 SULT1A3 sulfotransferase family 1A member 3 
10.1196 0.1721 F3 coagulation factor III, tissue factor 
10.1087 0.1764 ID1 inhibitor of DNA binding 1, HLH protein 
9.9288 0.1805 GLI1 GLI family zinc finger 1 
9.8984 0.1812 SYT16 synaptotagmin 16 
9.8119 0.1819 HIST1H3A histone cluster 1 H3 family member a 
9.7494 0.1824 LMNB1 lamin B1 
9.7319 0.1833 CNN2 calponin 2 
9.5970 0.1864 PRL prolactin 
9.5815 0.1876 PTGES3L prostaglandin E synthase 3 like 
9.4995 0.1918 OXTR oxytocin receptor 
9.3506 0.1919 RASGRP1 RAS guanyl releasing protein 1 
9.3334 0.1924 SYCP2L synaptonemal complex protein 2 like 
9.3129 0.1933 PLA2G2A phospholipase A2 group IIA 
9.1356 0.2039 ANO4 anoctamin 4 
9.1004 0.2083 ARHGDIB Rho GDP dissociation inhibitor beta 
9.0399 0.2107 GLIPR2 GLI pathogenesis related 2 
8.9303 0.2117 CD200 CD200 molecule 
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8.9037 0.2120 CDKN2B cyclin dependent kinase inhibitor 2B 
8.8893 0.2183 RHBDL2 rhomboid like 2 
8.8060 0.2244 TET1 tet methylcytosine dioxygenase 1 
8.5031 0.2247 KCNN4 potassium calcium-activated channel subfamily N member 4 
8.4446 0.2302 BDNF brain derived neurotrophic factor 
8.4278 0.2341 CRABP2 cellular retinoic acid binding protein 2 
8.4207 0.2376 CILP cartilage intermediate layer protein 
8.2698 0.2387 CCL11 C-C motif chemokine ligand 11 
8.2284 0.2416 WTH3DI RAB6C-like 
8.1777 0.2426 CLIC3 chloride intracellular channel 3 
8.1738 0.2431 OPCML opioid binding protein/cell adhesion molecule like 
8.1635 0.2432 LGALS9 galectin 9 
8.1224 0.2436 UMODL1 uromodulin like 1 
8.0546 0.2457 CALB2 calbindin 2 
7.8920 0.2466 RASL11B RAS like family 11 member B 
7.8590 0.2485 PRRX2 paired related homeobox 2 
7.7749 0.2486 CORO2A coronin 2A 
7.7584 0.2523 NOX4 NADPH oxidase 4 
7.7154 0.2555 RASSF2 Ras association domain family member 2 
7.7011 0.2566 NTRK2 neurotrophic receptor tyrosine kinase 2 
7.6615 0.2579 EGLN3 egl-9 family hypoxia inducible factor 3 
7.6200 0.2585 CDA cytidine deaminase 
7.6102 0.2592 RSPH4A radial spoke head 4 homolog A 
7.5703 0.2606 CSRP2 cysteine and glycine rich protein 2 
7.5008 0.2660 OLFM2 olfactomedin 2 
7.3854 0.2675 FGF9 fibroblast growth factor 9 
7.3710 0.2702 XG Xg blood group 
7.3529 0.2728 RAPGEF4 Rap guanine nucleotide exchange factor 4 
7.3050 0.2759 TSPAN2 tetraspanin 2 
7.2458 0.2765 OLFML2B olfactomedin like 2B 
7.1969 0.2788 LMTK3 lemur tyrosine kinase 3 
7.1058 0.2838 TREH trehalase 
7.0696 0.2868 JPH2 junctophilin 2 
7.0614 0.2874 MYADM myeloid associated differentiation marker 
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7.0065 0.2874 BIRC7 baculoviral IAP repeat containing 7 
7.0054 0.2938 ATRNL1 attractin like 1 
6.8786 0.3016 LUZP2 leucine zipper protein 2 
6.8630 0.3046 SLX1A SLX1 homolog A, structure-specific endonuclease subunit 
6.8359 0.3076 SAMD11 sterile alpha motif domain containing 11 
6.8093 0.3104 ITGB1BP2 integrin subunit beta 1 binding protein 2 
6.7261 0.3116 WFDC1 WAP four-disulfide core domain 1 
6.7149 0.3190 EPHA3 EPH receptor A3 
6.7028 0.3199 EPB41L4B erythrocyte membrane protein band 4.1 like 4B 
6.6794 0.3228 LRRC17 leucine rich repeat containing 17 
6.6539 0.3276 UHRF1 ubiquitin like with PHD and ring finger domains 1 
6.6508 0.3307 KSR1 kinase suppressor of ras 1 
6.6373 0.3338 FAM181B family with sequence similarity 181 member B 
6.6078 0.3342 RP11-849H4.2 Putative short transient receptor potential channel 2-like protein 
6.5624 0.3393 ADAM19 ADAM metallopeptidase domain 19 
6.4773 0.3399 GSTT2B glutathione S-transferase theta 2B (gene/pseudogene) 
6.4297 0.3417 JADE1 jade family PHD finger 1 
6.3525 0.3430 HOPX HOP homeobox 
6.2709 0.3437 WISP2 WNT1 inducible signaling pathway protein 2 
6.2553 0.3463 SRRM3 serine/arginine repetitive matrix 3 
6.2325 0.3485 IL17B interleukin 17B 
6.1909 0.3505 OLR1 oxidized low density lipoprotein receptor 1 
6.1805 0.3505 OR2B6 olfactory receptor family 2 subfamily B member 6 
6.1628 0.3544 TRIL TLR4 interactor with leucine rich repeats 
6.1593 0.3556 SYT3 synaptotagmin 3 
6.1558 0.3567 TAC3 tachykinin 3 
6.1316 0.3570 FST follistatin 
6.0911 0.3583 FSCN2 fascin actin-bundling protein 2, retinal 
6.0507 0.3585 NUAK2 NUAK family kinase 2 
6.0502 0.3603 MEX3A mex-3 RNA binding family member A 
6.0359 0.3631 HEYL hes related family bHLH transcription factor with YRPW motif-like 
5.9151 0.3639 LMCD1 LIM and cysteine rich domains 1 
5.9095 0.3658 HIST1H2BO histone cluster 1 H2B family member o 
5.8627 0.3676 FAM19A5 family with sequence similarity 19 member A5, C-C motif chemokine like 
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5.8573 0.3689 NREP neuronal regeneration related protein 
5.8419 0.3713 AC015688.3  
5.8293 0.3727 CALD1 caldesmon 1 
5.8269 0.3731 ASPN asporin 
5.7969 0.3749 CLSTN2 calsyntenin 2 
5.6873 0.3779 PRPS1 phosphoribosyl pyrophosphate synthetase 1 
5.6776 0.3786 WNT11 Wnt family member 11 
5.6623 0.3791 CDH6 cadherin 6 
5.6583 0.3820 PALLD palladin, cytoskeletal associated protein 
5.6183 0.3847 C16orf87 chromosome 16 open reading frame 87 
5.6141 0.3848 TPM1 tropomyosin 1 (alpha) 
5.6094 0.3861 XAF1 XIAP associated factor 1 
5.6051 0.3870 SGK223 Tyrosine-protein kinase SgK223 
5.5269 0.3874 GATA6 GATA binding protein 6 
5.5062 0.3891 TAGLN transgelin 
5.5002 0.3901 FAM133A family with sequence similarity 133 member A 
5.4844 0.3915 LOXL1 lysyl oxidase like 1 
5.4618 0.3918 C12orf73 chromosome 12 open reading frame 73 
5.3986 0.3939 ESCO2 establishment of sister chromatid cohesion N-acetyltransferase 2 
5.3871 0.3996 DZIP1L DAZ interacting zinc finger protein 1 like 
5.3801 0.3997 NLRP1 NLR family pyrin domain containing 1 
5.3797 0.4026 ALOX5AP arachidonate 5-lipoxygenase activating protein 
5.3415 0.4060 FSCN1 fascin actin-bundling protein 1 
5.3364 0.4073 AQP1 aquaporin 1 (Colton blood group) 
5.3042 0.4105 ZCCHC18 zinc finger CCHC-type containing 18 
5.2945 0.4171 EFNB2 ephrin B2 
5.2788 0.4176 MISP mitotic spindle positioning 
5.2776 0.4212 TC2N tandem C2 domains, nuclear 
5.2605 0.4230 NOG noggin 
5.2452 0.4246 TMEM92 transmembrane protein 92 
5.1804 0.4249 SLC38A5 solute carrier family 38 member 5 
5.1782 0.4249 ETV6 ETS variant 6 
5.1782 0.4253 CALY calcyon neuron specific vesicular protein 
5.1530 0.4260 PDLIM7 PDZ and LIM domain 7 
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5.0934 0.4266 KCNH1 potassium voltage-gated channel subfamily H member 1 
5.0717 0.4269 SRF serum response factor 
5.0677 0.4284 NTS neurotensin 
5.0661 0.4291 PPME1 protein phosphatase methylesterase 1 
5.0569 0.4326 RFPL4A ret finger protein like 4A 
5.0568 0.4327 TTC9 tetratricopeptide repeat domain 9 
5.0457 0.4339 IVNS1ABP influenza virus NS1A binding protein 
5.0371 0.4342 BGN biglycan 
5.0035 0.4374 PECAM1 platelet and endothelial cell adhesion molecule 1 
4.9848 0.4386 C9orf3 chromosome 9 open reading frame 3 
4.9806 0.4395 NEFH neurofilament heavy polypeptide 
4.9805 0.4445 MARCKSL1 MARCKS like 1 
4.9538 0.4457 RASD2 RASD family member 2 
4.9327 0.4458 TGM1 transglutaminase 1 
4.9062 0.4474 CST1 cystatin SN 
4.8994 0.4489 HABP2 hyaluronan binding protein 2 
4.8822 0.4507 SORBS2 sorbin and SH3 domain containing 2 
4.8760 0.4513 LIMK2 LIM domain kinase 2 
4.8744 0.4527 NOTCH3 notch 3 
4.8708 0.4621 SGCA sarcoglycan alpha 
4.8686 0.4627 TYRP1 tyrosinase related protein 1 
4.8677 0.4631 USP43 ubiquitin specific peptidase 43 
4.8498 0.4633 UCP3 uncoupling protein 3 
4.8466 0.4646 UACA uveal autoantigen with coiled-coil domains and ankyrin repeats 
4.8404 0.4663 DIO2 deiodinase, iodothyronine type II 
4.8016 0.4666 NKD1 naked cuticle homolog 1 
4.7891 0.4669 KCTD16 potassium channel tetramerization domain containing 16 
4.7672 0.4689 PDE4C phosphodiesterase 4C 
4.7521 0.4693 SORBS1 sorbin and SH3 domain containing 1 
4.7417 0.4706 DNAJB5 DnaJ heat shock protein family (Hsp40) member B5 
4.7194 0.4719 STK38L serine/threonine kinase 38 like 
4.6980 0.4724 ZCCHC12 zinc finger CCHC-type containing 12 
4.6792 0.4725 APOL4 apolipoprotein L4 
4.6704 0.4728 LRRC4B leucine rich repeat containing 4B 
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4.6658 0.4737 FRMPD3 FERM and PDZ domain containing 3 
4.6592 0.4746 OPN3 opsin 3 
4.6482 0.4749 LANCL2 LanC like 2 
4.6444 0.4769 MAP3K7CL MAP3K7 C-terminal like 
4.6321 0.4792 KLC3 kinesin light chain 3 
4.6199 0.4810 SOX9 SRY-box 9 
4.6170 0.4813 DDAH1 dimethylarginine dimethylaminohydrolase 1 
4.6140 0.4841 THBS1 thrombospondin 1 
4.5972 0.4842 NPR3 natriuretic peptide receptor 3 
4.5952 0.4848 PRG4 proteoglycan 4 
4.5767 0.4858 ZNF93 zinc finger protein 93 
4.5607 0.4878 ALDH1B1 aldehyde dehydrogenase 1 family member B1 
4.5513 0.4918 CGB7 chorionic gonadotropin beta subunit 7 
4.5416 0.4972 FGF1 fibroblast growth factor 1 
4.5288 0.4973 SMCO2 single-pass membrane protein with coiled-coil domains 2 
4.5046 0.4974 IL21R interleukin 21 receptor 
4.4939 0.4997 TXNDC5 thioredoxin domain containing 5 
 
relevant genes missing 
the > 2-fold requirement   
2.9998 0.5907 ACTA1 actin, alpha 1, skeletal muscle 
2.9060 0.6459 TGFBR1 transforming growth factor beta receptor 1 
2.1811 1.4010 TGFB1 transforming growth factor beta 1 
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